


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
3829.01-1

In Re Application Of: **WILLIAM J. WECHTER, ET AL.**



Serial No.
10/678,430

Filing Date
OCTOBER 3, 2003

Examiner
N/A

Group Art Unit
1615

Title: **R-NSAID ESTERS AND THEIR USE**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR


☐ the fee set forth in 37 CFR 1.17(p).

BEST AVAILABLE COPY

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
3829.01-1

In Re Application: **WILLIAM J. WECHTER, ET AL.**



Serial No.

10/678,430

Filing Date

OCTOBER 3, 2003

Examiner

N/A

Group Art Unit

1615

R-NSAID ESTERS AND THEIR USE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **16-1331** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail


I certify that this document and fee is being deposited on **FEBRUARY 4, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

HANA VERNY

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: **FEBRUARY 4, 2004**

HANA VERNY (REG. NO. 30,518)
PETERS, VERNY, JONES & SCHMITT L.L.P.
385 SHERMAN AVENUE, SUITE 6
PALO ALTO, CA 94306
TELEPHONE: (650)324-1677
FACSIMILE: (650)324-1678

BEST AVAILABLE COPY

CC:

APPLICA
O I P E
FEB 09 2004
1056
PATENT & TRADEMARK
REFERENCE

OTHER		ART (Including Author, Title, Date, Pertinent Pages, Etc.)
	G	Kato, et al., Studies on Scavengers of Active Oxygen Species. 1. Synthesis and Biological Activity of 2- <i>O</i> -Alkylascorbic Acids, <u>J. Med. Chem.</u> , 31:793-798 (1988).
	H	Manfredini, et al., Novel Antiosidant Agents Deriving From Molecular Combinations of <u>Vitamins C and E Analogues</u> : 3,4-Dihydroxy-5(<i>R</i>)-[2(<i>R,S</i>)-(6-hydroxy-2,5,7,8-tetramethylchroman-2(<i>R,S</i>)-yl-methyl)-[1,3]dioxolan-4(<i>S</i>)-yl]-5 <i>H</i> -furan-2-one and 3- <i>O</i> -Octadecyl Deerivatives, <u>Bioorganic & Medical Chemistry</u> , 8:2791-2801 (2000).
	I	Manfredini, et al., Design, Synthesis and Activity of Ascorbic Acid Prodrugs of Nipecotic, Kinurenic and Diclophenamic Acids, Liable to Increase Neurotropic Activity, <u>Journal of Medicinal Chemistry</u> , (November 2001).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY